Human Brain Cell U-87 MG based Proliferation Assay Service
Creative Biolabs' service provides the critical bridge between candidate discovery and preclinical validation by delivering robust, quantitative IC50 data on compound potency against the highly reliable U-87 MG glioblastoma line. By focusing on low-passage cell integrity and reproducible data, our results directly inform strategic decisions, ensuring only the most promising candidates progress to complex in vivo or co-culture studies, thereby minimizing preclinical attrition and expense.
Background Applications Workflow Publication Why Choose Us FAQs Customer Review Related Services Contact Us
U-87 MG: The Essential Model for Glioblastoma Research
Glioblastoma (GBM) is the most malignant primary brain tumor, demanding innovative, potent therapies. The U-87 MG cell line is an internationally recognized model for GBM studies, known for its consistent growth kinetics and established molecular profile. Rigorous scientific literature, including studies on passage-induced changes, highlights the necessity of using low-passage cells to preserve key malignant characteristics, such as high PI3K/Akt and TGF-β signaling activity. Our service ensures this molecular integrity is maintained, supporting the credibility of all derived anti-proliferative IC50 data.
Applications of Our Assay
|
Drug screening
|
Toxicity testing
|
Cancer research
|
Genetic studies
|
Biomarker discovery
|
|
By measuring the proliferation of U-87 MG cell lines in the presence of different drug compounds, you can identify potential candidates for further testing.
|
By measuring the effects of samples on cell proliferation, you can determine their potential harmful effects on human health.
|
By studying the proliferation of U-87 MG cell lines, you can gain insights into the mechanisms of cancer growth and potential therapeutic targets.
|
By manipulating gene expression in U-87 MG cell lines and measuring their proliferation, you can elucidate the functions of various genes in the context of cancer and other diseases.
|
By measuring the proliferation of U-87 MG cell lines in response to different stimuli, you can identify molecular markers that are altered in diseased cells compared to healthy cells.
|
Contact our immuno-oncology experts today to discuss optimizing your drug discovery strategy with the industry-leading U-87 MG proliferation assay service and strategic model selection guidance.
Scientific Rigor: Our Quantitative Assay Methodology
Our service is engineered for quantitative accuracy and high-throughput efficiency, ensuring that every result is robust, reliable, and directly scalable for further development. The standard procedure is meticulously optimized:
Publication
This study investigated the role of 14-3-3β in the aggressive brain tumor glioblastoma (U87MG cells). Using an inducible system for complete knockout, researchers demonstrated that the loss of 14-3-3β significantly impaired cellular proliferation and 3D spheroid formation. The findings confirm 14-3-3β's critical contribution to glioblastoma malignancy, supporting its strong potential as a therapeutic target for these highly aggressive tumors.
Fig.1 Inhibition of 14-3-3β by siRNA reduces U87MG cell proliferation. 1
Why Choose Us
Creative Biolabs offers unparalleled commitment to scientific integrity in neuro-oncology screening, leveraging over two decades of expertise. We guarantee high-confidence preclinical results by implementing strict passage control for reproducibility, using only low-passage cells to prevent cellular drift and preserve the expression of critical malignancy pathways. This ensures your IC50 data accurately reflects efficacy against the true, aggressive GBM phenotype. Furthermore, our deep expertise in targets like the 14-3-3β protein provides highly nuanced mechanistic insights to accelerate your program.
Experience the Creative Biolabs Advantage - Get a Quote Today
FAQs
Q1: Why is strict passage control so important for the U-87 MG line?
A1: U-87 MG cells are known to undergo "molecular drift" over long-term culture. We strictly control passage number to ensure the cells used for your assay retain the authentic, aggressive GBM phenotype, guaranteeing your IC50 results are meaningful and predictive.
Q2: Can this assay be used to compare my drug against standard GBM therapies like temozolomide (TMZ)?
A2: Absolutely. Our assay includes both vehicle controls and positive controls (such as TMZ) as standard practice. This comparison allows you to directly quantify your compound's relative potency, which is essential for defining its competitive advantage and designing effective combination strategies.
Q3: How do you handle compounds with low solubility in aqueous media?
A3: We have established protocols for handling poorly soluble compounds, primarily utilizing DMSO as a vehicle at concentrations proven not to interfere with cell viability. We also offer specialized formulation and stability testing as a related service to ensure the compound remains active and available during the assay incubation period.
Customer Review
-
Quality Control
Using Creative Biolabs' U-87 MG proliferation assay in our research has significantly facilitated confidence in our early-stage IC50 data. Their use of low-passage cells is a critical precaution that differentiates them from core facilities. - Dr. P***r K
-
Target Validation
Using Creative Biolabs' assay in our research has significantly improved the validation of our novel 14-3-3β inhibitor. We were able to link the compound's proliferation inhibition to clear western blot results in the same assay run, confirming the mechanism of action with robust, reproducible data. - D***d C
Related Services
To complement your U-87 MG potency data and achieve full preclinical success, Creative Biolabs offers several highly relevant services:
Efficacy Models
Creative Biolabs supports the rapid progress of anticancer immunotherapies by offering integrated preclinical testing services, including in vivo pharmacology, drug metabolism and pharmacokinetics, and toxicology to assess therapeutic efficacy.
Learn More →
Self-destruction Assays
Creative Biolabs developed an original self-destruction assay analysis platform to test the efficacy of engineered mammalian cells in cancer immunotherapies. We offer tailored solutions to help you optimize self-destructing cancer cells for your projects.
Learn More →
Contact Us
Creative Biolabs offers the industry's most scientifically rigorous U-87 MG proliferation assay service, providing high-confidence IC50 data supported by stringent, low-passage quality control and expert mechanistic insights into GBM's critical signaling pathways.
Contact Our Team for More Information and to Discuss Your Project
Reference
-
Gallo, Kellie, et al. "Inducible Knockout of 14-3-3β Attenuates Proliferation and Spheroid Formation in a Human Glioblastoma Cell Line U87MG." Brain Sciences 13.6 (2023). Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/brainsci13060868
